ArticleJournal of neuro-oncology2026
Is looking at the tip of the iceberg sinking our ship? A longitudinal cohort study on the patterns of evolution on treatment of non-enhancing FLAIR lesions in primary CNS lymphoma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrent response criteria for primary CNS lymphoma (PCNSL) focus on contrast-enhancing lesions, potentially overlooking the significance of non-enhancing FLAIR abnormalities (NEFA). The significance of these NEFA lesions are poorly understood, and we conducted this study to evaluate the prognostic value of these lesions in patients with PCNSL. MATERIALS AND
methodsThis retrospective IEC approved longitudinal cohort study analyzed 112 PCNSL patients (2008–2024) with serial MRIs spanning baseline, interim, end of induction treatment and subsequent follow up MRIs. Two blinded neuroradiologists assessed the temporal evolution of characteristics of the NEFA lesions (discrete mass forming/convex FLAIR hyperintensities ≥ 5 mm) on standard high dose methotrexate based treatment at baseline, interim (8 weeks), end-of-treatment (16 weeks), and subsequent follow-up scans. Increase in NEFA was defined as new/enlarging NEFA (≥ 25% increase in size) and progression was defined (standard IPCG) as frank areas of new onset enhancement. The end point of the study was determined on the patient’s outcome - relapse / progressive disease. Kaplan-Meier graphs were used for survival analysis.
resultsPatients with NEFA anytime during the course of treatment had significantly higher progression rates (46.6% vs. 7.4%, p < 0.001). In patients on post induction therapy follow-up, increase in NEFA lesions was associated with higher risk of death with HR = 11.620 (1.26,106.81), p = 0.007. Baseline NEFA predicted progression in 41.2% (p = 0.004). 91% patients with increasing NEFA at follow up MRI eventually progressed (0.007). Deep/infratentorial lesions and baseline T1 volume > 12.8 cm³ independently predicted poorer PFS (p < 0.05).
conclusionsNEFA evolution is a robust biomarker of treatment failure in PCNSL, often preceding contrast-enhancing progression. Incorporating NEFA assessment into response criteria could improve risk stratification and enable earlier intervention.
Indexed as
Identifiers
41712114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.